Form 8-K - Current report:
SEC Accession No. 0001558370-24-002480
Filing Date
2024-03-05
Accepted
2024-03-05 16:15:23
Documents
16
Period of Report
2024-03-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mxct-20240304x8k.htm   iXBRL 8-K 37654
2 EX-99.1 mxct-20240304xex99d1.htm EX-99.1 34370
3 GRAPHIC mxct-20240304xex99d1001.jpg GRAPHIC 7633
  Complete submission text file 0001558370-24-002480.txt   210774

Data Files

Seq Description Document Type Size
4 EX-101.SCH mxct-20240304.xsd EX-101.SCH 3129
5 EX-101.LAB mxct-20240304_lab.xml EX-101.LAB 15917
6 EX-101.PRE mxct-20240304_pre.xml EX-101.PRE 10319
17 EXTRACTED XBRL INSTANCE DOCUMENT mxct-20240304x8k_htm.xml XML 4792
Mailing Address 9713 KEY WEST AVENUE, SUITE 400 ROCKVILLE MD 20850
Business Address 9713 KEY WEST AVENUE, SUITE 400 ROCKVILLE MD 20850 301-517-5556
MAXCYTE, INC. (Filer) CIK: 0001287098 (see all company filings)

EIN.: 522210438 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40674 | Film No.: 24720573
SIC: 8731 Services-Commercial Physical & Biological Research
(CF Office: 08 Industrial Applications and Services)